With over 75 years of combined experience, the Innomab
founders use their accumulated knowledge to identify the
most promising early stage projects and the most cost–
effective and time-efficient development pathways.
Development operations are carried out both by the
founders themselves and through a global virtual-network
of high-quality consultants and contract research and
Innomab specializes in development of innovative
monoclonal antibodies in oncology. The team also
possesses broad experience in other therapeutic areas
and with other types of molecules.
Innomab provides its drug development expertise and
capability to client companies on a fee-for-service basis.
To these consulting contracts, Innomab brings the highest
level of experience, care, and accountability.
Innomab is a C-corporation, incorporated in Delaware,
based in Redwood City, California, and wholly owned by
the three founders.